Find Technologies

  • Renal Selective Unsaturated Englerin Analogues
    •
       Ref: E-072-2014 | Updated: Aug 01, 2018 | NCI
  • Enhanced Immunogenicity Against HIV-1 Using a DNA-prime Poxvirus Vaccination
    •
       Ref: E-157-2000 | Updated: Aug 01, 2018 | NCI
  • Nucleic Acid Nanoparticles (NANP) and Methods of Using Same for Controlled Immunomodulation
    •
       Ref: E-069-2018 | Updated: Aug 14, 2018 | NCI
  • Method for Reproducible Differentiation of Clinical Grade Retinal Pigment Epithelium Cells
    •
       Ref: E-212-2015 | Updated: Aug 14, 2018 | NEI
  • Topical Sodium Nitrate Ointment for Sickle Cell Disease
    •
       Ref: E-149-2014 | Updated: Aug 15, 2018 | NIH-CC
  • Robotic Exoskeleton for Treatment of Crouch Gait in Children with Cerebral Palsy (CP)
    •
       Ref: E-096-2016 | Updated: Apr 25, 2018 | CC
  • Fatty Acid Derivatives and Their Use
    •    Ref: E-151-2017 | Updated: Apr 25, 2018 | NIA
  • Fully Human Antibodies and Antibody Drug Conjugates Targeting Tumor Endothelial Marker 8 (TEM8) for the Treatment of Cancer
    •
       Ref: E-344-2013 | Updated: Apr 07, 2020 | NCI
  • Methods and Compositions for Treating Genetically Linked Diseases of the Eye
    •
       Ref: E-284-2012 | Updated: Aug 13, 2020 | NEI
  • Scytovirin Domain 1 Related Polypeptides
    •    Ref: E-180-2005 | Updated: Jul 27, 2018 | NCI
  • Strategies to Protect Mammalian Neural Tissue Against Cold and Potentially Other Metabolic Stresses and Physical Damages
    •
       Ref: E-165-2017 | Updated: Oct 12, 2018 | NEI
  • A Novel Carbohydrate Antibody to GalNac1-3Gal and Its Application for Cancer Diagnostic and Prognosis
    •
       Ref: E-058-2009 | Updated: Feb 16, 2018 | NCI
  • Cancer-reactive T cells from Peripheral Blood
    •
       Ref: E-149-2015 | Updated: Feb 16, 2018 | NCI
  • Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptors (CARs)
    •
       Ref: E-183-2017 | Updated: Mar 13, 2018 | NCI
  • Efficient Cell-Free Production of Papillomavirus Gene Transfer Vectors
    •
       Ref: E-298-2016 | Updated: Feb 12, 2019 | NCI
  • Combination Therapy for Prostate and Breast Cancer
    •
       Ref: E-257-2014 | Updated: Oct 27, 2017 | NCI
  • MRI-Based Method for Characterizing Axonal Microstructure in Traumatic Brain Injury
    •
       Ref: E-008-2015 | Updated: Nov 02, 2017 | NICHD
  • NSAIDs that Assist the Treatment of Human Diseases
    •
       Ref: E-131-2011 | Updated: Feb 21, 2018 | NCI
  • Methods of Producing Effective T-cell Populations Using Akt Inhibitors
    •
       Ref: E-013-2016 | Updated: Dec 05, 2017 | NCI
  • Therapeutics for Neurodegenerative Disorders and Cancer Using Lenalidomide Analogs
    •
       Ref: E-045-2012 | Updated: Apr 03, 2018 | NIA
  • IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)
    •
       Ref: E-247-2015 | Updated: Jan 17, 2018 | NCI
  • Conserved Elements Vaccine for HIV
    •    Ref: E-132-2012 | Updated: Jun 28, 2019 | NCI
  • Nucleic Acid Nanoparticles for Triggering RNA Interference
    •
       Ref: E-156-2014 | Updated: Apr 07, 2020 | NCI
  • Functionally-Interdependent Shape-Switching Nucleic Acid Nanoparticles
    •
       Ref: E-277-2016 | Updated: Oct 23, 2017 | NCI
  • Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors
    •
       Ref: E-115-2015 | Updated: Apr 18, 2017 | NCI
  • Compounds that Interfere with the Androgen Receptor Complex
    •
       Ref: E-162-2009 | Updated: Aug 17, 2020 | NCI
  • Prognostic Biomarkers for Patients with Early Stage Lung Cancer
    •    Ref: E-048-2012 | Updated: Apr 09, 2018 | NCI
  • Clinical Outcome Predictors for Mantle Cell Lymphoma
    •
       Ref: E-131-2016 | Updated: Oct 25, 2017 | NCI
  • A New Class of Stable Heptamethine Cyanine Fluorophores and Biomedical Applications Thereof
    •
       Ref: E-271-2014 | Updated: Mar 20, 2018 | NCI
  • Niclosamide for Treating Adrenocortical Cancer (ACC)
    •
       Ref: E-089-2016 | Updated: Jul 16, 2018 | NCI
  • A Sensitive, High Throughput Pseudovirus-Based Papillomavirus Neutralization Assay for HPV 16 and HPV 18
    •
       Ref: E-137-2004 | Updated: Jul 19, 2018 | NCI
  • Anti-bacterial Treatments Using Peptide-Based Inhibitors of the STAT3-IL10 Pathway
    •
       Ref: E-278-2014 | Updated: Jan 18, 2017 | NCI
  • Anti-Py1235-Met Immunological Binding Reagent as Cancer Diagnostic
    •
       Ref: E-130-2016 | Updated: Feb 13, 2017 | NCI
  • New T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors
    •
       Ref: E-153-2016 | Updated: Mar 02, 2017 | NCI
  • Devices for Improved Tissue Cryopreservation and Recovery
    •
       Ref: E-094-2016 | Updated: Apr 13, 2020 | NEI
  • Treatment of GPR101-Related, Growth Hormone-Related Disorders Such as Gigantism, Dwarfism or Acromegaly
    •
       Ref: E-039-2016 | Updated: Jan 03, 2019 | NICHD
  • Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
    •
       Ref: E-134-2016 | Updated: Apr 13, 2020 | NEI
  • Computer-Aided Diagnostic for Use in Multiparametric MRI for Prostate Cancer
    •
       Ref: E-183-2016 | Updated: Jun 23, 2017 | CC
  • Use of Heterodimeric IL-15 in Adoptive Cell Transfer
    •
       Ref: E-132-2016 | Updated: Sep 07, 2017 | NCI
  • Photoactivatable Lipid-based Nanoparticles as a Vehicle for Dual Agent Delivery
    •
       Ref: E-482-2013 | Updated: Apr 13, 2020 | NCI
  • Near-IR Light-Cleavable Antibody Conjugates and Conjugate Precursors
    •
       Ref: E-245-2016 | Updated: Sep 29, 2017 | NCI
  • Brachyury-directed Vaccine for the Prevention or Treatment of Cancers
    •
       Ref: E-055-2011 | Updated: Mar 20, 2018 | NCI
  • Immunogenic Antigen Selective Cancer Immunotherapy
    •
       Ref: E-089-2009 | Updated: Mar 21, 2018 | NIA
  • Overexpression of Phf19 on T Cells Enhances Therapeutic Effects of T Cell-Based Therapies (such as Chimeric Antigen Receptor [CAR] Therapies)
    •
       Ref: E-107-2017 | Updated: Jul 13, 2018 | NCI
  • Therapeutic antibody-drug conjugates targeting CD56-positive cancers
    •
       Ref: E-221-2015 | Updated: Apr 07, 2020 | NCI
  • Vaccines for HIV
    •
       Ref: E-087-2015 | Updated: Apr 17, 2018 | NCI
  • B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia
    •
       Ref: E-163-2009 | Updated: Apr 17, 2018 | NCI
  • Ratio Based Biomarkers for the Prediction of Cancer Survival
    •
       Ref: E-025-2009 | Updated: Mar 29, 2018 | NCI
  • Analogues of Withanolide E Sensitize Cancer Cells Toward Apoptosis
    •
       Ref: E-051-2016 | Updated: Apr 07, 2020 | NCI
  • A549 Cells: Lung Carcinoma Cell Line for Adenovirus
    •
       Ref: E-129-2009 | Updated: May 30, 2018 | NCI
  • Methods of making and using dopamine receptor selective antagonists/partial agonists
    •
       Ref: E-053-2016 | Updated: Nov 13, 2018 | NIDA
  • Genetically Engineered Mouse-Derived Allograft for Preclinical Studies of Metastatic Melanoma
    •
       Ref: E-291-2015 | Updated: Jul 19, 2018 | NCI
  • Target for Anti-Tumor Immune Responses
    •
       Ref: E-070-2010 | Updated: Apr 19, 2018 |
  • Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma)
    •
       Ref: E-035-2013 | Updated: Apr 07, 2020 | NCI
  • Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics
    •
       Ref: E-765-2013 | Updated: Jun 18, 2018 | NCI
  • Cell Lines Expressing Nuclear and/or Mitochondrial RNAse H1
    •
       Ref: E-273-2012 | Updated: Mar 09, 2018 | NICHD
  • Gene Therapy Vector for the Treatment of Glycogen Storage Disease Type Ia (GSD-Ia)
    •
       Ref: E-039-2015 | Updated: Mar 09, 2018 | NICHD
  • Thalidomide Analogs that Inhibit Inflammation and Angiogenesis
    •
       Ref: E-208-2015 | Updated: Aug 31, 2016 | NIA
  • Chimeric Antigen Receptors (CARs) for Treating Lymphoma and Other Cancers
    •
       Ref: E-001-2016 | Updated: Mar 23, 2018 | NCI
  • Modified griffithsin tandemers for enhanced activity and reduced viral aggregation
    •
       Ref: E-034-2013 | Updated: Mar 29, 2018 | NCI
  • Optical Trap Methods to Determine the Viscoelastic Properties of Biological Materials
    •
       Ref: E-251-2015 | Updated: Apr 23, 2018 |
  • Biomarker signature development: microRNAs for biodosimetry
    •
       Ref: E-066-2015 | Updated: Mar 06, 2017 | NCI
  • Cell Line for Production of Recombinant Human Tissue Inhibitor of Metalloproteinase-2
    •
       Ref: E-216-2017 | Updated: Aug 13, 2020 | NCI
  • Anti-SLAMF7 Chimeric Antigen Receptors
    •
       Ref: E-158-2018 | Updated: Oct 15, 2018 | NCI
  • Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20
    •
       Ref: E-205-2018 | Updated: Nov 08, 2018 | NCI
  • 89Zr-Oxine Complex for In Vivo PET Imaging of Labelled Cells and Associated Methods
    •
       Ref: E-080-2014 | Updated: Aug 31, 2016 | NCI
  • Novel Anti-HIV Proteins from Coral Reefs
    •
       Ref: E-295-2012 | Updated: Mar 26, 2018 | NCI
  • Radiographic Marker for Portable Chest and Abdominal X-Rays
    •
       Ref: E-063-2011 | Updated: Jul 19, 2018 | NIHCC
  • Micro-Dose Calibrator for Pre-clinical Radiotracer Assays
    •
       Ref: E-241-2016 | Updated: Jul 27, 2019 | FNLCR
  • Nitric Oxide Based Therapeutics for the Treatment of Lung Cancer
    •
       Ref: E-025-2010 | Updated: Apr 24, 2018 | NCI
  • Improved PE-based Targeted Toxins: A Therapeutic with Increased Effectiveness
    •
       Ref: E-269-2009 | Updated: Aug 31, 2016 | NCI
  • MUC-1 Tumor Antigen Agonist Epitopes for Enhancing T-cell Responses to Human Tumors
    •
       Ref: E-001-2012 | Updated: May 30, 2018 | NCI
  • Diagnostics and Therapeutics for Adrenocortical Carcinomas
    •
       Ref: E-026-2011 | Updated: May 30, 2018 |
  • Silica-Coated Nanodiamonds for Imaging and Delivery of Therapeutic Agents
    •
       Ref: E-175-2012 | Updated: Oct 06, 2020 | NCI
  • Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276
    •
       Ref: E-145-2019 | Updated: Jun 17, 2020 | NCI
  • Software for Automated Generation of Density Maps
    •
       Ref: E-162-2012 | Updated: Jun 07, 2018 |
  • Modified POTE Peptides for Cancer Immunotherapy
    •
       Ref: E-003-2010 | Updated: Jun 19, 2018 | NCI
  • Software for Modeling Delivery and Penetration of Antibody Conjugates
    •
       Ref: E-060-2012 | Updated: Jun 07, 2018 | NCI
  • BODIPY-FL Nilotinib (Tasigna) for Use in Cancer Research
    •
       Ref: E-009-2010 | Updated: May 30, 2018 | NCI
  • Nitroxyl (HNO) Releasing Therapeutics
    •
       Ref: E-019-2010 | Updated: Mar 29, 2018 | NCI
  • Dual-Function Protein ATIA for Diagnostics and Therapeutics of Glioblastoma
    •    Ref: E-178-2009 | Updated: May 30, 2018 | NCI
  • Improved Personalized Cancer Immunotherapy
    •
       Ref: E-059-2013 | Updated: Mar 09, 2018 | NCI
  • Use of Cucurbitacins and Withanolides for the Treatment of Cancer
    •
       Ref: E-050-2010 | Updated: Aug 13, 2020 | NCI
  • Immunocompetent Mouse Model for Tracking Cancer Progression
    •
       Ref: E-173-2010 | Updated: Jun 18, 2018 | NCI
  • Software for Accurate Segmentation of Cell Nuclei in Breast Tissue
    •
       Ref: E-106-2010 | Updated: Apr 18, 2018 | NCI
  • Tempol: A Commercially-Available Nitroxide as a Cancer Therapeutic
    •
       Ref: E-133-2009 | Updated: Jul 19, 2018 | NCI
  • Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4)
    •
       Ref: E-158-2010 | Updated: Feb 05, 2018 | NCI
  • Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters
    •
       Ref: E-132-2011 | Updated: Aug 12, 2020 | NCI
  • Phosphodiesterase as a target for cancer therapeutics
    •
       Ref: E-199-2010 | Updated: Sep 06, 2016 | NCI
  • Substrate Reduction Therapy for Smith-Lemli-Opitz Syndrome and Related Disorders
    •
       Ref: E-206-2007 | Updated: Mar 20, 2020 | NICHD
  • Diagnostic Marker for Improving Treatment Outcomes of Hepatitis C
    •    Ref: E-217-2011 | Updated: Apr 20, 2018 | NCI
  • Cancer Therapies Using Engineered Monomeric Fc Molecules
    •
       Ref: E-019-2012 | Updated: Apr 13, 2020 | NCI
  • Virus-Like Particles That Can Deliver Proteins and RNA
    •
       Ref: E-264-2011 | Updated: Sep 30, 2016 | NCI
  • Mouse Xenograft Model for Mesothelioma
    •
       Ref: E-302-2009 | Updated: Mar 27, 2018 | NCI
  • Human Monoclonal Antibodies Cross-reacting to Insulin-like Growth Factors IGF-I and IGF-II as Potential Anti-tumor Agents
    •
       Ref: E-068-2011 | Updated: May 04, 2018 | NCI
  • New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines
    •    Ref: E-089-2010 | Updated: Mar 09, 2018 | NCI
  • Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease
    •
       Ref: E-101-2010 | Updated: Aug 13, 2020 | NIA
  • Engineered Biological Pacemakers
    •
       Ref: E-134-2009 | Updated: Nov 05, 2018 | NIA
  • Osmogels: A New Method for Stabilizing Weak Molecular Complex Interactions
    •
       Ref: E-214-2009 | Updated: Sep 06, 2016 | NICHD
  • Biomarker for Predicting Taxane Chemotherapy Outcome
    •
       Ref: E-191-2009 | Updated: Aug 09, 2017 | NCI

    Pages


    Displaying 1201 - 1300 of 1371

    Category Index

    Office of Technology Transfer, Office of Intramural Research, National Institutes of Health

    6011 Executive Blvd, Suite 325, Rockville, MD 20852 | Phone: 301-496-7057